Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Monthly Archives: September 2016

Congressional Leaders Put 21st Century Medical-Research Bill on Priority List

Capitol Dome HEALTHCAREWashington, DC, September 30, 2016The Wall Street Journal reported Congressional leaders said Thursday that legislation to inject billions of dollars into federal biomedical research and ease drug approvals is a main priority for the lame-duck session after the November elections.

The measure is one of the biggest pieces of legislation left on the table as lawmakers left town on Thursday to campaign for re-election.

The fact that both Senate Majority Leader Mitch McConnell (R., Ky.) and House Speaker Paul Ryan (R., Wis.) put it on the agenda for the session suggests it has a strong chance of advancing in the weeks after the election. Continue reading

Congress Passes Spending Bill Frees Up $1.1 Billion to Fight Zika

Capitol Dome flag faveWashington, DC, September 30, 2016The Wall Street Journal reported that legislation Congress cleared on Wednesday to keep the federal government running will free up $1.1 billion for efforts to research and treat the Zika virus, advance a vaccine and control mosquitoes.

The virus, which is mostly spread by mosquitoes, has infected more than 23,000 people in the U.S. and its territories.

Administration officials have warned that available funds to combat Zika were close to running out. The emergency funding was seen as critical to halting the spread of the virus, whose health risks include serious birth defects, pregnancy problems and a nervous system sickness. Continue reading

Governor Christie Names Aaron Fichtner as Acting Commissioner of Labor

Aaron Fichtner

Aaron Fichtner

Trenton, NJ, September 28, 2016 — Governor Chris Christie on September 23 announced the appointment of Aaron R. Fichtner, Ph.D., as Acting Commissioner of the Department of Labor and Workforce Development, adding that he will formally nominate Dr. Fichtner on Monday to succeed Commissioner Harold J. Wirths.

Dr. Fichtner has been a part of the Department since 2010, serving as Deputy Commissioner since 2012.

Governor Christie said, “The New Jersey Department of Labor and Workforce Development has come a long way during the past six years, reinventing our reemployment efforts during the darkest days of the recession to focus getting jobseekers trained for positions in the Garden State’s emerging and most promising industry clusters.” Continue reading

Sen. Diane Allen Bill Legalizing Telemedicine in New Jersey Passes Committee

Trenton Capital Dome  MoonTrenton, NJ, September 27, 2016 — Legislation sponsored by Senator Diane Allen (R-Burlington) authorizing the use of telemedicine in New Jersey has been advanced by the Senate Health Committee.

“Telemedicine is especially vital for patients who suffer from chronic illness, seniors who are homebound, and families who live in rural areas where they would have to travel very far to receive medical care,” Senator Allen said.

“No one should have to choose between paying for groceries and traveling to see a doctor,” Senator Allen continued.  “By legalizing telemedicine, we can bring the cost of healthcare down and expand access to a variety of health services for millions of new patients.” Continue reading

Tufts CSDD Report: Cost of Bringing New Drug to Market Surpasses $2.8 Billion.

Research 1Boston, MA, September 27, 2016 — The most recent analysis by the Tufts Center for the Study of Drug Development of the average cost to develop and gain marketing approval for a new drug — pegged at $2.558 billion — was published in the May 2016 issue of Journal of Health Economics.

The article contains more detailed analyses and discussion than were presented in November 2014 when Tufts CSDD first disclosed primary results on the cost of developing a new prescription medicine, after having previously submitted the study to the peer-reviewed publication.

The $2.558 billion figure per approved compound is based on estimated average out-of-pocket costs of $1.395 billion and time costs (expected returns that investors forego while a drug is in development) of $1.163 billion. Continue reading

The Fourth Annual BioNJ CEO Summit Took It OVER the Top; BIO CEO Jim Greenwood Keynotes

BioNJ SquareTrenton, NJ, September 27, 2016 ― The Fourth Annual BioNJ CEO Summit that took place last week, September 23 at the Bridgewater Marriott, brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s challenging and evolving market access and commercialization environment.

The stellar lineup of speakers dove into the issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.

“Because Patients Can’t WaitSM, bringing new treatments and drugs to the Patients who need them is always at the heart of our programs,” said BioNJ President and CEO Debbie Hart. Continue reading

U.S. Sees Sizable Increase in R&D Spending; Totals Rose by $20 Billion in 2014; Similar Increase Estimated for 2015

R&D 5Arlington, VA, September 26, 2016 — The National Science Foundation reports that U.S. research and development (R&D) performance rose to $477.7 billion in 2014 — an increase of $21.1 billion over the previous year — and is estimated to hit $499.3 billion in 2015, according to a new report from the National Center for Science and Engineering Statistics (NCSES).

The NCSES report looks at two different aspects of the U.S. system: the performance of R&D by businesses, government agencies, higher education institutions and other organizations, and the funding sources used by these sectors to perform that R&D. Continue reading

Rutgers President Robert Barchi Plans to Stay Beyond 5-Year Commitment

Robert Barchi, M.D., Ph.D.

Robert Barchi, M.D., Ph.D.

New Brunswick, NJ, September 25, 2016 ― Adam Clark reports in The Star-Ledger that when Rutgers University lured Robert Barchi, M.D., Ph.D. out of retirement to become its president in 2012, he told reporters he was making at least a five-year commitment to the university.

Now, in the midst of his fifth year at the helm of Rutgers, the 70-year-old is happier than ever with the state of the university and feels more energized than he has any point in his tenure, he told NJ Advance Media in an interview Wednesday.

“As of right now, I have no intention of stepping down this year,” Dr. Barchi said. “As long as I think we are on a positive trajectory… I am willing to continue in the job for a while.” Continue reading

Event: NJBIA to Host Second Annual Innovation Summit on November 2

Innovation button touch 2Trenton, NJ, September 25, 2016 ― The New Jersey Business & Industry Association (NJBIA) will host its Second Annual Innovation Summit on Wednesday, November 2 at the Princeton Plasma Physics Laboratory from 8:30 a.m. to 2:00 p.m.

The half day event will bring together thought leaders and feature both venture capitalists and internationally recognized CEOs who will tell their story on what it takes to cultivate innovation in a business.

The Summit, designed for both local startups and legacy corporations, also will highlight the resources our state’s six research universities and state and local government have to offer.  Continue reading

Two Startups Based on Rutgers Inventions Chosen as Best University Startups; Showcased at U.S. Capitol

Rutgers 250 AnniversaryNew Brunswick, NJ, September 24, 2016 ― Two new companies built on Rutgers inventions were presented on September 20 at University Startup Demo Day, an event in the U.S. Capitol Building for members of Congress members and staff, as well as venture capitalists, angel investors and corporate representatives.

The two Rutgers spinouts are:

  • Celvive Inc., which is refining a stem-cell technology for regenerative medicine applications, such as helping patients recover from spinal cord injury.